These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
498 related articles for article (PubMed ID: 27287929)
1. Control and Eradication Strategies of Hepatitis B Virus. Shih C; Chou SF; Yang CC; Huang JY; Choijilsuren G; Jhou RS Trends Microbiol; 2016 Sep; 24(9):739-749. PubMed ID: 27287929 [TBL] [Abstract][Full Text] [Related]
2. Upcoming pharmacological developments in chronic hepatitis B: can we glimpse a cure on the horizon? Alonso S; Guerra AR; Carreira L; Ferrer JÁ; Gutiérrez ML; Fernandez-Rodriguez CM BMC Gastroenterol; 2017 Dec; 17(1):168. PubMed ID: 29268704 [TBL] [Abstract][Full Text] [Related]
3. New therapies for chronic hepatitis B. Bitton Alaluf M; Shlomai A Liver Int; 2016 Jun; 36(6):775-82. PubMed ID: 26854115 [TBL] [Abstract][Full Text] [Related]
4. The current status and future directions of hepatitis B antiviral drug discovery. Tang L; Zhao Q; Wu S; Cheng J; Chang J; Guo JT Expert Opin Drug Discov; 2017 Jan; 12(1):5-15. PubMed ID: 27797587 [TBL] [Abstract][Full Text] [Related]
11. Review article: novel therapies for hepatitis B virus cure - advances and perspectives. Lin CL; Kao JH Aliment Pharmacol Ther; 2016 Aug; 44(3):213-22. PubMed ID: 27302653 [TBL] [Abstract][Full Text] [Related]
12. Latest developments in the treatment of hepatitis B. Dandri M; Petersen J Minerva Gastroenterol Dietol; 2016 Mar; 62(1):88-102. PubMed ID: 26448309 [TBL] [Abstract][Full Text] [Related]
13. Clinical relevance of the study of hepatitis B virus covalently closed circular DNA. Kumar R; Pérez-Del-Pulgar S; Testoni B; Lebossé F; Zoulim F Liver Int; 2016 Jan; 36 Suppl 1():72-7. PubMed ID: 26725901 [TBL] [Abstract][Full Text] [Related]
14. Metabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapeutics. Guo JT; Guo H Antiviral Res; 2015 Oct; 122():91-100. PubMed ID: 26272257 [TBL] [Abstract][Full Text] [Related]
16. Involvement of Host ATR-CHK1 Pathway in Hepatitis B Virus Covalently Closed Circular DNA Formation. Luo J; Luckenbaugh L; Hu H; Yan Z; Gao L; Hu J mBio; 2020 Feb; 11(1):. PubMed ID: 32071277 [TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for Chronic Hepatitis B Virus Infection. Bertoletti A; Le Bert N Gut Liver; 2018 Sep; 12(5):497-507. PubMed ID: 29316747 [TBL] [Abstract][Full Text] [Related]
18. Emerging pipeline drugs for hepatitis B infection. Cox N; Tillmann H Expert Opin Emerg Drugs; 2011 Dec; 16(4):713-29. PubMed ID: 22195605 [TBL] [Abstract][Full Text] [Related]
19. Immune balance in Hepatitis B Infection: Present and Future Therapies. Vyas AK; Jindal A; Hissar S; Ramakrishna G; Trehanpati N Scand J Immunol; 2017 Jul; 86(1):4-14. PubMed ID: 28387980 [TBL] [Abstract][Full Text] [Related]
20. Novel therapeutic approaches for hepatitis B virus covalently closed circular DNA. Ohno M; Otsuka M; Kishikawa T; Yoshikawa T; Takata A; Koike K World J Gastroenterol; 2015 Jun; 21(23):7084-8. PubMed ID: 26109795 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]